UPDATED: EMA safety committee seeks more info on heart inflammation following Pfizer Covid-19 vaccine
The European Medicines Agency’s safety committee said Friday that it’s aware of cases of inflammation of the heart muscle and inflammation of the membrane around the heart, mainly reported following vaccination with Pfizer’s Covid-19 vaccine, known in Europe as Comirnaty.
“There is no indication that these cases are due to the vaccine,” the EMA’s Pharmacovigilance Risk Assessment Committee said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.